DK2384327T3 - Forbindelse med kondenseret ring og anvendelse deraf. - Google Patents

Forbindelse med kondenseret ring og anvendelse deraf.

Info

Publication number: DK2384327T3
Authority: DK; Denmark
Prior art keywords: condensed ring; ring connection; connection; condensed; ring
Prior art date: 2009-01-30

Application number

DK10703532.1T

Other languages

English (en)

Inventor

Tsuyoshi Maekawa

Hideyuki Igawa

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-30

Filing date

2010-01-29

Publication date

2013-10-28

2010-01-29 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2013-10-28 Application granted granted Critical

2013-10-28 Publication of DK2384327T3 publication Critical patent/DK2384327T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

DK10703532.1T 2009-01-30 2010-01-29 Forbindelse med kondenseret ring og anvendelse deraf. DK2384327T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2009020720		2009-01-30
PCT/JP2010/051651 WO2010087515A1 (en)	2009-01-30	2010-01-29	Fused ring compound and use thereof

Publications (1)

Publication Number	Publication Date
DK2384327T3 true DK2384327T3 (da)	2013-10-28

Family

ID=42026435

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK10703532.1T DK2384327T3 (da)	2009-01-30	2010-01-29	Forbindelse med kondenseret ring og anvendelse deraf.

Country Status (37)

Country	Link
US (4)	US8283353B2 (da)
EP (1)	EP2384327B1 (da)
JP (2)	JP4892649B1 (da)
KR (1)	KR20110113758A (da)
CN (2)	CN103788097B (da)
AR (1)	AR075344A1 (da)
AU (1)	AU2010208863A1 (da)
CA (1)	CA2750710C (da)
CL (1)	CL2011001848A1 (da)
CO (1)	CO6362011A2 (da)
CR (1)	CR20110463A (da)
CY (1)	CY1114530T1 (da)
DK (1)	DK2384327T3 (da)
DO (1)	DOP2011000249A (da)
EA (1)	EA019823B1 (da)
EC (1)	ECSP11011294A (da)
ES (1)	ES2433225T3 (da)
GE (1)	GEP20135961B (da)
HK (1)	HK1162505A1 (da)
HR (1)	HRP20131017T1 (da)
IL (1)	IL214283A0 (da)
MA (1)	MA33071B1 (da)
ME (1)	ME01621B (da)
MX (1)	MX2011008058A (da)
MY (1)	MY152946A (da)
NZ (1)	NZ594606A (da)
PE (1)	PE20120593A1 (da)
PL (1)	PL2384327T3 (da)
PT (1)	PT2384327E (da)
RS (1)	RS53012B (da)
SG (1)	SG173135A1 (da)
SI (1)	SI2384327T1 (da)
TN (1)	TN2011000368A1 (da)
TW (2)	TW201444848A (da)
UY (1)	UY32409A (da)
WO (1)	WO2010087515A1 (da)
ZA (1)	ZA201105867B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2384327T3 (da) *	2009-01-30	2013-10-28	Takeda Pharmaceutical	Forbindelse med kondenseret ring og anvendelse deraf.
EP2655375B1 (fr)	2010-12-23	2014-12-03	Sanofi	Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
CZ304252B6 (cs) *	2011-04-11	2014-01-29	Zentiva, K. S.	Způsob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátů a jejich převedení na azilsartan
IL263429B (en) *	2016-06-20	2022-08-01	Novartis Ag	Crystalline forms of triazolopyrimidine compound
WO2019067560A1 (en)	2017-09-26	2019-04-04	Ecolab Usa Inc.	ANTIMICROBIAL COMPOSITIONS AND ACID / ANIONIC VIROCIDES AND USES THEREOF
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en)	2019-02-15	2022-07-12	Incyte Corporation	Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en)	2019-03-05	2022-10-18	Incyte Corporation	Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en)	2019-03-29	2020-10-08	Incyte Corporation	Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en)	2019-05-01	2020-11-05	Incyte Corporation	N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en)	2019-05-01	2022-09-20	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
EP4013750A1 (en)	2019-08-14	2022-06-22	Incyte Corporation	Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CA3157681A1 (en)	2019-10-11	2021-04-15	Incyte Corporation	Bicyclic amines as cdk2 inhibitors
CN112745319B (zh) *	2019-10-30	2022-06-17	中国科学院上海药物研究所	一类取代三环结构的化合物、其制备方法及用途
US11981671B2 (en)	2021-06-21	2024-05-14	Incyte Corporation	Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2672892B1 (fr) *	1991-02-20	1994-01-14	Synthelabo	Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique.
US5472967A (en)	1991-02-20	1995-12-05	Synthelabo	4-pyrimidinone derivatives their preparation and their application in therapy
IL102183A (en)	1991-06-27	1999-11-30	Takeda Chemical Industries Ltd	The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
TW251288B (da) *	1991-06-27	1995-07-11	Takeda Dharm Industry Co Ltd
IT1250749B (it)	1991-08-02	1995-04-21	Luso Farmaco Inst	Composti eterociclici ad attivita' a ii antagonista
US5387747A (en)	1992-02-24	1995-02-07	Laboratoires Upsa	Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present
US5389632A (en)	1992-02-24	1995-02-14	Laboratoires Upsa	Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
FR2687677B1 (fr) *	1992-02-24	1996-10-11	Union Pharma Scient Appl	Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
IT1263804B (it)	1993-01-22	1996-09-03	Luso Farmaco Inst	Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista
GB9406573D0 (en)	1994-03-31	1994-05-25	Merck Sharp & Dohme	Medicaments
WO1996040256A1 (en)	1995-06-07	1996-12-19	G.D. Searle & Co.	Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone
PT831911E (pt)	1995-06-07	2002-09-30	Searle & Co	Terapeutica de combinacao de espironolactona e antagonista da angiotensina ii para o tratamento de insuficiencia cardiaca congestiva
DK0831910T3 (da)	1995-06-07	2002-05-21	Searle & Co	Kombinationsterapi med epoxy-steroid aldosteronantagonist og angiotensin II-receptorantagonist til behandling af kongestivt hjertesvigt
WO1996040255A2 (en)	1995-06-07	1996-12-19	G.D. Searle & Co.	Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
FR2812876B1 (fr)	2000-08-08	2002-09-27	Galderma Res & Dev	Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
SE0101579D0 (sv)	2001-05-04	2001-05-04	Astrazeneca Ab	New compounds
US7232828B2 (en)	2002-08-10	2007-06-19	Bethesda Pharmaceuticals, Inc.	PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
TW200418835A (en)	2003-01-24	2004-10-01	Tanabe Seiyaku Co	A pyrazolopyrimidine compound and a process for preparing the same
WO2005020984A2 (en)	2003-08-29	2005-03-10	Aaipharma Inc.	Method of reducing the risk of oxidative stress
CA2553724A1 (en) *	2004-02-03	2005-08-18	Abbott Laboratories	Aminobenzoxazoles as therapeutic agents
KR101194622B1 (ko)	2004-06-02	2012-10-29	다케다 야쿠힌 고교 가부시키가이샤	접합 헤테로시클릭 화합물
US20050288272A1 (en)	2004-06-23	2005-12-29	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
BRPI0512379A (pt)	2004-06-23	2008-03-11	Solvay Pharm Gmbh	composições farmacêuticas compreendendo inibidores de nep, inibidores do sistema de produção de endotelina endógena e antagonista do receptor at1
CA2616150A1 (en)	2005-07-27	2007-02-01	Talia Weinstein	Inhibition of the renin-angiotensin system for the treatment of renal, vascular and cartilage pathology
WO2007051007A2 (en)	2005-10-28	2007-05-03	Novartis Ag	Combination of antihypertensives with cholesterol-lowering agent
WO2007053406A1 (en)	2005-10-28	2007-05-10	Novartis Ag	Combinations of antihypertensive and cholesterol lowering agents
US20080064871A1 (en)	2006-05-26	2008-03-13	Japan Tobacco Inc.	Production Method of Nitrogen-Containing Fused Ring Compounds
EP2078205A2 (en)	2006-11-09	2009-07-15	Ore Pharmaceuticals Inc.	Breast cancer screening and treatment methods
US20090012052A1 (en)	2006-11-09	2009-01-08	Ore Pharmaceuticals Inc.	Method for treating er+ breast cancer
BRPI0719060A2 (pt) *	2006-11-24	2014-02-04	Takeda Pharmaceutical	Composto, prodroga, agente farmacêutico, métodos para inibir um receptor de angiotensina ii e/ou ativar um receptor ativado com proliferador de peroxisoma, e para prevenir ou tratar doenças ou condições, e, uso de um composto
WO2008143262A1 (ja)	2007-05-21	2008-11-27	Takeda Pharmaceutical Company Limited	複素環化合物およびその用途
CA2703019A1 (en)	2007-09-20	2009-03-26	University Of Rochester	Method and compositions for treatment or prevention of inflammatory conditions
PT2268612E (pt)	2008-03-24	2014-11-13	Novartis Ag	Inibidores de metaloprotease de matriz à base de arilsulfonamidas
WO2009137465A2 (en)	2008-05-05	2009-11-12	University Of Rochester	Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
DK2384327T3 (da)	2009-01-30	2013-10-28	Takeda Pharmaceutical	Forbindelse med kondenseret ring og anvendelse deraf.

2010
- 2010-01-29 DK DK10703532.1T patent/DK2384327T3/da active
- 2010-01-29 RS RS20130472A patent/RS53012B/en unknown
- 2010-01-29 US US12/696,147 patent/US8283353B2/en not_active Expired - Fee Related
- 2010-01-29 ES ES10703532T patent/ES2433225T3/es active Active
- 2010-01-29 EA EA201101138A patent/EA019823B1/ru not_active IP Right Cessation
- 2010-01-29 KR KR1020117020049A patent/KR20110113758A/ko not_active Application Discontinuation
- 2010-01-29 AR ARP100100240A patent/AR075344A1/es unknown
- 2010-01-29 NZ NZ594606A patent/NZ594606A/xx not_active IP Right Cessation
- 2010-01-29 PT PT107035321T patent/PT2384327E/pt unknown
- 2010-01-29 CN CN201310750040.3A patent/CN103788097B/zh not_active Expired - Fee Related
- 2010-01-29 SG SG2011053741A patent/SG173135A1/en unknown
- 2010-01-29 MA MA34132A patent/MA33071B1/fr unknown
- 2010-01-29 GE GEAP201012358A patent/GEP20135961B/en unknown
- 2010-01-29 AU AU2010208863A patent/AU2010208863A1/en not_active Abandoned
- 2010-01-29 UY UY0001032409A patent/UY32409A/es not_active Application Discontinuation
- 2010-01-29 ME MEP-2013-131A patent/ME01621B/me unknown
- 2010-01-29 CN CN201080014441.7A patent/CN102369205B/zh not_active Expired - Fee Related
- 2010-01-29 EP EP10703532.1A patent/EP2384327B1/en active Active
- 2010-01-29 MX MX2011008058A patent/MX2011008058A/es active IP Right Grant
- 2010-01-29 CA CA2750710A patent/CA2750710C/en not_active Expired - Fee Related
- 2010-01-29 TW TW103125956A patent/TW201444848A/zh unknown
- 2010-01-29 MY MYPI2011003554 patent/MY152946A/en unknown
- 2010-01-29 PL PL10703532T patent/PL2384327T3/pl unknown
- 2010-01-29 JP JP2011525329A patent/JP4892649B1/ja not_active Expired - Fee Related
- 2010-01-29 SI SI201030403T patent/SI2384327T1/sl unknown
- 2010-01-29 TW TW99102537A patent/TWI468410B/zh not_active IP Right Cessation
- 2010-01-29 PE PE2011001418A patent/PE20120593A1/es not_active Application Discontinuation
- 2010-01-29 WO PCT/JP2010/051651 patent/WO2010087515A1/en active Application Filing
- 2010-01-29 US US13/146,989 patent/US8592431B2/en not_active Expired - Fee Related
2011
- 2011-06-30 JP JP2011146858A patent/JP5676379B2/ja not_active Expired - Fee Related
- 2011-07-25 IL IL214283A patent/IL214283A0/en unknown
- 2011-07-27 TN TN2011000368A patent/TN2011000368A1/fr unknown
- 2011-07-29 CL CL2011001848A patent/CL2011001848A1/es unknown
- 2011-07-29 DO DO2011000249A patent/DOP2011000249A/es unknown
- 2011-08-09 US US13/205,967 patent/US8921379B2/en not_active Expired - Fee Related
- 2011-08-11 ZA ZA2011/05867A patent/ZA201105867B/en unknown
- 2011-08-26 CR CR20110463A patent/CR20110463A/es unknown
- 2011-08-29 CO CO11109923A patent/CO6362011A2/es active IP Right Grant
- 2011-08-30 EC EC2011011294A patent/ECSP11011294A/es unknown
2012
- 2012-03-27 HK HK12103030.2A patent/HK1162505A1/xx not_active IP Right Cessation
2013
- 2013-10-22 US US14/059,868 patent/US9115136B2/en not_active Expired - Fee Related
- 2013-10-25 HR HRP20131017AT patent/HRP20131017T1/hr unknown
- 2013-10-25 CY CY20131100941T patent/CY1114530T1/el unknown

Also Published As

Publication number	Publication date
CN102369205B (zh)	2014-10-29
ES2433225T3 (es)	2013-12-10
US8592431B2 (en)	2013-11-26
CY1114530T1 (el)	2017-01-25
CR20110463A (es)	2011-12-01
TN2011000368A1 (en)	2013-03-27
PL2384327T3 (pl)	2013-12-31
CA2750710C (en)	2018-09-04
CL2011001848A1 (es)	2012-02-03
US8921379B2 (en)	2014-12-30
US20100197683A1 (en)	2010-08-05
NZ594606A (en)	2013-06-28
AU2010208863A1 (en)	2011-09-08
ECSP11011294A (es)	2011-09-30
HK1162505A1 (en)	2012-08-31
EA019823B1 (ru)	2014-06-30
MY152946A (en)	2014-12-15
TW201031669A (en)	2010-09-01
EP2384327A1 (en)	2011-11-09
JP2012513952A (ja)	2012-06-21
EP2384327B1 (en)	2013-07-31
SG173135A1 (en)	2011-08-29
US20110288087A1 (en)	2011-11-24
AR075344A1 (es)	2011-03-23
HRP20131017T1 (hr)	2013-12-06
ME01621B (me)	2014-09-20
JP5676379B2 (ja)	2015-02-25
TWI468410B (zh)	2015-01-11
JP2011251970A (ja)	2011-12-15
RS53012B (en)	2014-04-30
ZA201105867B (en)	2012-10-31
GEP20135961B (en)	2013-11-11
CO6362011A2 (es)	2012-01-20
PE20120593A1 (es)	2012-05-21
US8283353B2 (en)	2012-10-09
US20140046056A1 (en)	2014-02-13
MX2011008058A (es)	2011-09-01
US9115136B2 (en)	2015-08-25
US20110294832A1 (en)	2011-12-01
CN103788097A (zh)	2014-05-14
CN103788097B (zh)	2016-03-30
WO2010087515A1 (en)	2010-08-05
CA2750710A1 (en)	2010-08-05
CN102369205A (zh)	2012-03-07
JP4892649B1 (ja)	2012-03-07
MA33071B1 (fr)	2012-02-01
PT2384327E (pt)	2013-11-07
EA201101138A1 (ru)	2012-04-30
DOP2011000249A (es)	2011-09-15
SI2384327T1 (sl)	2013-12-31
UY32409A (es)	2010-08-31
IL214283A0 (en)	2011-09-27
TW201444848A (zh)	2014-12-01
KR20110113758A (ko)	2011-10-18

Publication	Publication Date	Title
DK2384327T3 (da)	2013-10-28	Forbindelse med kondenseret ring og anvendelse deraf.
DK2467173T3 (da)	2019-07-29	Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
DK2479174T3 (da)	2017-11-27	6-aminoquinazolin- eller 3-cyanquinolinderivater, fremstillingsfremgangsmåder og farmaceutiske anvendelser deraf
BRPI1012883A2 (pt)	2018-06-12	dispositivo intercorporal.
BR112012002349A2 (pt)	2015-10-13	composto,e, uso do mesmo
BRPI0909770A2 (pt)	2015-08-11	Vacina, e, kit
DK2137307T3 (da)	2014-11-03	Termostabile asparaginaser
BRPI1016117A2 (pt)	2016-04-12	derivados de isoxazol-isoxazol e isoxasol-isotiazol.
EP2515946A4 (en)	2015-10-07	NANOCONJUGATES AND COMPOSITIONS OF NANOCONJUGATES
DK2276760T3 (da)	2014-05-26	Kondenserede ringforbindelser og anvendelse deraf
DK3150721T3 (da)	2019-07-01	Pankreascancermarkører og detekteringsfremgangsmåder
BR112012003844A2 (pt)	2016-11-16	vacinas de pttv e diagnóstico
EP2405390A4 (en)	2014-07-09	Image search device and image search method
BR112012000519A2 (pt)	2016-02-16	correia de fixação e dispositivo de fixação.
BR112012008101A2 (pt)	2016-03-01	bolsa de ostomia.
EP2448252A4 (en)	2012-11-28	IMAGE CAPTURE DEVICE, IMAGE CAPTURE METHOD, AND IMAGE CAPTURE CIRCUIT
EP2393836A4 (en)	2012-09-26	SAM-6 VARIANTS, TARGET AND METHODS OF USING SAME
HK1172321A1 (zh)	2013-04-19	-替代- -替代- 咪唑 -四嗪- -酮化合物及其用途
BRPI1008708A2 (pt)	2016-03-08	gastroscópio.
SI3066996T1 (sl)	2021-09-30	Naprava kolčnega sklepa
BRPI1008596A2 (pt)	2016-03-15	sistema, e, aparelho
BR112012003860A2 (pt)	2015-09-01	Combinação, e, composição nutricional
BRPI1008147A2 (pt)	2016-03-08	composição de xampu concentrado e xampu centrado
DK2430057T3 (da)	2014-01-13	Temperaturfølsomme co-polymerer og anvendelser heraf
DK2226545T3 (da)	2013-11-04	Rørelement og anvendelse heraf